Pulmonary Arterial Hypertension

Additional data strengthens Cereno's CS1 in PAH

Following promising Phase IIa results for the drug candidate CS1 against pulmonary arterial hypertension (PAH) in October 2024, Cereno Scientific is now delivering...

Cereno Scientific to evaluate CS1 with advanced imaging technology

Cereno Scientific announces that a substudy with CS1...

Cereno Scientific CEO on new treatments for rare diseases

BioStock met with Cereno Scientific CEO Sten R. Sörensen...

Intervju
Video
Cereno_PhaseIIa_results

Positive Phase IIa results for Cereno, clear path forward

Cereno Scientific recently announced positive topline results from phase...
Cereno CEO comment

Cereno's CEO comments on advancement with CS1 and CS014

Cereno Scientific reports new progress with two of...

Intervju
CLS_new French study

Cereno builds momentum for major clinical milestones

Cereno Scientific has announced clear progress in its...
Etienne Adriansen CBO Cereno Scientific

Cereno Scientific's CBO on his new role

Cereno Scientific's clinical and preclinical programs in cardiovascular...

Intervju
Fredrik Radencrantz

Iconovo invests in pharmaceutical sales in the Nordics

Iconovo has begun the development of its subsidiary Iconovo Pharma...

Intervju

Cereno Scientific is changing

When the FDA granted orphan drug status for CS1 in pulmonary...
FDA

FDA grants Cereno Scientific's lead candidate Orphan Drug Designation

Cereno Scientific is now accelerating the build-out of its platform...